Guidelines for the Use of Conventional and Newer Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis
- 1 May 2009
- journal article
- review article
- Published by Springer Nature in Drugs & Aging
- Vol. 26 (4) , 273-293
Abstract
Treatment strategies in the management of rheumatoid arthritis (RA) have significantly changed in the past decade. The early use of disease-modifying antirheumatic drugs (DMARDs) is the basis of this new treatment strategy. Because these agents alter the natural disease course of RA, early aggressive intervention results in better outcomes with respect to future structural damage and disability. The arrival of the ‘biologic agents’ era in rheumatology has further improved the therapeutic options in patients with RA. A significant portion of individuals with this ailment are elderly, with approximately one-third of patients experiencing their first symptoms after the age of 60 years. Yet, many elderly patients with RA do not receive optimal treatment. Although the reasons for this have not been completely defined, it seems clinicians are reluctant to use DMARDs in the elderly because of uncertainty regarding their efficacy and safety in this population. The aging process is associated with important changes in drug pharmacokinetics and pharmacodynamics. It appears that the former, mainly through decreased renal clearance, is responsible for an increased incidence of adverse effects with some DMARDs. The old are also more susceptible to infection than the young, making prevention of infectious disease through vaccination of particular importance; however, healthcare professionals should be aware that some DMARDs, including biologic agents, may interfere with responses to vaccination. The available data, although limited, suggest that DMARDs, including some biologic agents, are similarly effective in the old and the young, while maintaining very good adverse effect profiles. Therefore, the elderly with RA should not be excluded from receiving optimal treatment with these medications. At the same time, clinicians must be aware of the possible increased risk of drug toxicities, recognize the need to adjust therapy to match individual patient characteristics (i.e. renal function, co-morbidities, concomitant medication use or polypharmacy), and use the lowest possible effective dosage. This review describes the special considerations to be taken into account when administering conventional (synthetic) or biologic DMARDs to elderly patients with RA.Keywords
This publication has 187 references indexed in Scilit:
- Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part IArthritis & Rheumatism, 2007
- Treatment of older adult patients diagnosed with rheumatoid arthritis: Improved but not optimalArthritis Care & Research, 2007
- Are rheumatologists' treatment decisions influenced by patients' age?Rheumatology, 2006
- Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides.Journal of Clinical Investigation, 1998
- SulfasalazineDrugs, 1995
- Clinical Pharmacokinetics of Slow-Acting Antirheumatic DrugsClinical Pharmacokinetics, 1993
- The clinical features of elderly‐onset rheumatoid arthritis. A comparison with younger‐onset disease of similar durationArthritis & Rheumatism, 1985
- Efficacy of Low-Dose Methotrexate in Rheumatoid ArthritisNew England Journal of Medicine, 1985
- Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity — I. Disease modifying action on adjuvant arthritis of the ratInternational Journal of Immunopharmacology, 1985
- THERAPEUTIC SUPPRESSION OF TISSUE REACTIVITYThe American Journal of the Medical Sciences, 1951